DALLAS, April 20 /PRNewswire-FirstCall/ -- Austin Medical Technologies (OTC Pink Sheets: AMTK) is pleased to have Dr. Mark Golden join its Board of Advisors. Dr. Golden has a long history in anterior segment surgery, but has restricted his practice to Refractive Surgery for more than four years. He purchased the first microkeratome in the Midwest in 1990 for the use in ALK (the precursor of Lasik). He has trained refractive surgeons nationally and internationally and is a well-known lecturer to the eye care community. He has opened a number of laser centers around the United States and is the Medical Director of Doctors For Visual Freedom, a full service Refractive Surgical Center located in Northwest Suburban Chicago. Dr. Golden has performed more than 13,000 refractive procedures. He is pleased to work with Austin Medical Technologies because of his interest in efficiency and conservation of medical supplies. He states, “Carefully designed surgical packs eliminate waste and speed up the surgical process. It is an enormous convenience to know that everything needed for a procedure is in one spot. This saves time and therefore is a cost savings. It also means that excess supplies are not wasted by opening up individual packages that are too large for one surgical case.”
Kurt Tarter, President and CEO said, “We are fortunate to have Dr. Golden join our Board of Advisors. Dr. Golden is well respected in the community of Ophthalmology and is a forward thinker on new innovative technology. This will help Austin MedTech further expand its business in the upper Midwest where several large surgery centers are located.”
About Austin Medical Technologies, Inc.
Austin Medical Technologies delivers “DIRECT” from the manufacturer to the Surgeon, the only technology based, “Single Source Supply Solution” for custom sterile procedure trays (CPTs) and medical devices dedicated exclusively to the multi-specialty Ambulatory Surgery Center (ASC) market. Under the brand name eyeDirecti, Austin MedTech is initially focused on Ophthalmology owned and operated ASCs which consist of 2,500 practices with 15,000 surgeons performing 4.4 million surgical procedures annually at a supply cost of $400,000,000 per year. Visit our e-commerce site at http://www.eyedirecti.com/ .
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this communication (as well as information included in oral statements or other written statements made or to be made by Austin Medical Technologies, Inc. or its wholly owned subsidiaries) contains statements that are forward-looking, such as statements relating to the future anticipated direction of the medical and technology industries and plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of Austin Medical Technologies or its wholly owned subsidiaries. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financial activities, domestic and global economic conditions, changes in federal or state tax laws, and market competition factors. Keith Tarter of Austin Medical Technologies, Inc., +1-972-370-0197, or investors@austinmedtech.com
Austin Medical Technologies, Inc.
CONTACT: Keith Tarter of Austin Medical Technologies, Inc.,+1-972-370-0197, or investors@austinmedtech.com
